This article summarized the latest R&D progress of Selumetinib, the Mechanism of Action for Selumetinib, and the drug target R&D trends for Selumetinib.

Growth factors represent a class of polypeptides that regulate cell growth and various other cellular functions through binding with specific, high-affinity cell membrane receptors.

This article summarized the latest R&D progress of Peramivir, the Mechanism of Action for Peramivir, and the drug target R&D trends for Peramivir.

GSK plc has confirmed that Ojjaara(momelotinib), a daily oral JAK1/JAK2 and activin A receptor type 1 inhibitor, has received approval from the US FDA.

This article summarized the latest R&D progress of Pantethine, the Mechanism of Action for Pantethine, and the drug target R&D trends for Pantethine.

Toxoid Vaccine is essentially a bacterial toxin that is rendered harmless due to processing.

This article summarized the latest R&D progress of Pacritinib, the Mechanism of Action for Pacritinib, and the drug target R&D trends for Pacritinib.

Harpoon Therapeutics announced that AbbVie has offered a unique licensing opportunity for its HPN217 program, targeting BCMA, as per their Development and Option Agreement.

This article summarized the latest R&D progress of Nitrofurazone, the Mechanism of Action for Nitrofurazone, and the drug target R&D trends for Nitrofurazone.

HDAC6 is the largest member of the HDAC family, consisting of 1215 amino acids.

This article summarized the latest R&D progress of Lorlatinib, the Mechanism of Action for Lorlatinib, and the drug target R&D trends for Lorlatinib.

Vincerx Pharma, Inc. declared that the initial patient in the Phase 1 clinical trial has received treatment with VIP943.